UBS has cut its price target on Smith & Nephew PLC (LSE:SN) to 1,120p from 1,300p, warning that even the medical device group's recently reduced guidance for this year remains at risk.
The neutral rating is unchanged, with the new target implying about 3.5% upside from Monday's close of 1,082p.
Analyst Graham Doyle said investor interest has picked up sharply following the guidance cut and the unexpected departure of the finance director.
His conclusion is unflattering. To hit the 4% organic growth target for this year, Smith & Nephew would need roughly 6% growth in the second half, which would be its second strongest such performance in a decade.
UBS forecasts 3.2% instead, and models trading profit of $1.25 billion against management's $1.3 billion guidance.
The medium-term picture looks worse.
Management is targeting 6% to 7% organic revenue growth through 2028, against a 3.3% compound annual rate actually delivered between 2015 and 2025.
UBS models 4%, leaving its earnings forecasts 4% to 9% below consensus. The bank identifies three franchises accounting for roughly 10% of group revenue that now face fresh competition.
Santyl, a wound debridement ointment generating about $400 million a year, faces reimbursement pressure from prior authorisation requirements and a potential rival in MediWound's EscharEx, which beat it across several endpoints in a phase two head-to-head study and could launch from 2027.
OXINIUM, the nickel-free implant material worth roughly $100 million of US revenue, now competes with Stryker's Triathlon Gold, a possible $20 million headwind.
CORI, the handheld surgical robot with more than 1,100 installations and about $75 million of revenue, faces Stryker's newly launched Mako RPS, backed by an installed base exceeding 3,000 units.
The Landmark knee platform, due in the US this quarter, is described as strategically important but unlikely to shift the numbers near-term.
UBS argues most of the anticipated benefit is already in consensus estimates.
Valuation offers some cushion, with the shares on about 12 times forward earnings and a sum-of-the-parts calculation pointing to 1,370p.
Doyle notes such portfolio businesses rarely realise that value.
